

Conclusions

Neuronal uptake of normal and paraneoplastic IgGs requires the interaction of the Fc portion of the IgG molecule with previously uncharacterized neuronal FcγRI receptors. Our study provides a mechanism through which antibodies reactive with intracellular neuronal proteins could gain access to their target antigens to cause neuronal injury and neurological disease. The observation that neuronal antibody uptake can be blocked by normal IgG has possible implications for patient treatment.

Disclosure: Dr. Smith has nothing to disclose. The institution of an immediate family member of Dr. Liu has received research support from NIH. The institution of Mr. Carlson has received research support from Biogen. Mr. Carlson has received personal compensation in the range of \$100,000-\$499,999 for serving as a Employee as a Researcher with Veteran Affairs. Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Clarion. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for ExpertConnect. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for VielaBio. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Genentech. The institution of Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Alexion. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for GuidePoint. Dr. Clardy has received personal compensation in the range of \$10,000-\$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from Alexion Pharma. The institution of Dr. Clardy has received research support from Sumaira Foundation for NMO. The institution of Dr. Clardy has received research support from Immune Deficiency Foundation. The institution of Dr. Clardy has received research support from Western Institute for Veteran Research. The institution of Dr. Clardy has received research support from NIH/NINDS. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Grand Rounds Travel and Lodging with U of Iowa. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Speaker Honoraria for Grand Rounds with Barrow Neurological Institute. Dr. Greenlee has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink. Dr. Greenlee has received publishing royalties from a publication relating to health care. Dr. Greenlee has received publishing royalties from a publication relating to health care.

Anti-Tr/DNER Paraneoplastic Cerebellar Degeneration with Marked Cerebellar and Psychological Symptoms Responsive to Plasma Exchange

Paul Crane, DonRaphael Pratt Wynn, Dana DeWitt, John Greenlee

Objective

We present a patient who developed cerebellar degeneration and severe psychological symptoms leading to the diagnosis of Hodgkin's disease and detection of anti-Tr/DNER antibodies. The patient failed to respond methylprednisolone intravenous immunoglobulin G, rituximab, and tumor treatment but had significant improvement with plasma exchange (PLEX).

Background

Paraneoplastic cerebellar degeneration accompanying Hodgkin's disease may have its onset prior to detection of the underlying malignancy, during its course, or following treatment. The associated autoantibody, anti-Tr, is reactive with neuronal delta/notch-like epidermal growth factor-related receptors (DNER), an autoantibody not included in all paraneoplastic testing screens. The condition characterized by progressive cerebellar injury, and response to immunosuppressive therapy and tumor treatment is generally poor.

Design/Methods

Case Presentation: A 60-year-old male presented with diplopia, progressive loss of balance, and ataxia, with impaired short-term memory, confusion, and anger outbursts. Initial commercial screen for paraneoplastic autoantibodies was negative. Two months following his initial presentation he developed inguinal lymphadenopathy. He was diagnosed as having Hodgkin's Lymphoma Stage 1B and found by a second laboratory to have anti-Tr/DNER antibodies (Titer 1:3480; Reference range <1:240), an antibody not included in the initial testing panel. CSF analysis was notable for a protein of 92 mg/dL. MRI demonstrated normal findings for age.

Results

Treatment with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine (ABVD), pulse methylprednisolone, and intravenous immunoglobulin did not affect disease progression. Plasma exchange PLEX resulted in marked improvement. Symptoms worsened during subsequent treatment with intravenous immunoglobulins and rituximab but improved with further plasma exchange.

Conclusions

Although Hodgkin's disease is an important malignancy in paraneoplastic cerebellar degeneration, its associated autoantibody is not necessarily included in commercial paraneoplastic autoantibody screens, potentially leading to delay in diagnosis. Our patient's dramatic improvement with PLEX suggests that PLEX should be considered early in treatment, or where there is poor response to other treatment modalities.

Disclosure: Dr. Crane has nothing to disclose. Dr. Wynn has nothing to disclose. Dr. DeWitt has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Biogen. Dr. Greenlee has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink. Dr. Greenlee has received publishing royalties from a publication relating to health care. Dr. Greenlee has received publishing royalties from a publication relating to health care.

CASPR-2 Antibody Associated Autoimmunity in the Setting of COVID-19 (Infection, Vaccination, or Both?) and Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

Neda Sattarnezhad, Jamie McDonald, Anna Tomczak, Julia Sumera, Jacob Loeffler, May Han

Objective

To report a case of Anti-Contactin-Associated Protein-like2 (CASPR-2) autoimmunity in a patient with low-grade Chronic Lymphocytic Leukemia (CLL) following COVID-19 vaccination and infection.

Background

Anti-CASPR2 antibody disorder has been associated with neoplastic disorders like thymoma. Recent reports enlist COVID-19 as a potential trigger of CASPR2 autoimmunity. While the clinical presentations are similar, management differs based on the underlying etiology.

Design/Methods

We review a case of anti-CASPR2-antibody associated disorder with concurrent low grade CLL and recent history of COVID-19 vaccination and infection. Additionally, we review the literature and discuss the therapeutic challenges.

Results

A 73-years old male presented with five months of progressive fatigue, weight loss, diffuse sweating, muscle cramps, and neuropathic pain. He eventually developed bilateral upper and lower facial weakness. Patient

contracted a mild COVID-19 infection two months prior and COVID-19 vaccination one month prior to his symptom onset. His exam was remarkable for bilateral facial weakness, diffuse fasciculations and sensory neuropathy on his trunk and extremities. His diagnostic work up including bone marrow biopsy was consistent with a chronic lymphocytic leukemia (CLL)-like immunophenotype. Cerebrospinal fluid (CSF) analysis was remarkable for five WBC (lymph-dominant) and protein of 74 mg/dl. Serum paraneoplastic panel revealed positive CASPR2 antibody with a titer of 1:100. Magnetic Resonance Imaging (MRI) of the brain showed enhancement of bilateral cranial nerve VII. After lack of clinical response to IV methylprednisone (1 gram for 5 days), patient was treated with a single cycle of IV immunoglobulin (IVIG). He had complete recovery of his symptoms except for residual facial weakness. He remains stable at his six months post-treatment follow-up.

Conclusions

Anti-CASPR2 associated autoimmunity following COVID-19 infection or in the setting of CLL has previously been reported. However, cranial neuropathy in association with CASPR2 antibody has never been. A trial of IVIG could be beneficial in patients with viral-spike protein-induced autoimmunity and CLL who do not otherwise meet the criteria for CLL treatment.

Disclosure: Dr. Sattarnezhad has nothing to disclose. Dr. McDonald has nothing to disclose. Miss Tomczak has nothing to disclose. Miss Sumera has nothing to disclose. An immediate family member of Dr. Loeffler has received research support from National Science Foundation. The institution of an immediate family member of Dr. Loeffler has received research support from Amazon. May Han has nothing to disclose.

A Woman With Kelch-like Protein-11 Encephalitis and Unmasked Metastatic Carcinoma

Paunel Agyei, Rajesh Gupta

Objective

To illustrate a case of a woman with rhombencephalitis with antibodies to Kelch-like protein-11 (KLHL11) and a metastatic carcinoma.

Background

KLHL11 encephalitis is an autoimmune paraneoplastic syndrome first described in 2019. The clinical presentation consists of a brainstem cerebellar syndrome with symptoms of hearing loss, diplopia, vertigo and ataxia. This entity has been mostly described in male patients with associated testicular seminomas. Few cases have been described in women. This is a case of a woman with a history of hysterectomy and oophorectomy with KLHL11 encephalitis and an associated aortocaval tumor.

Design/Methods

NA.

Results

The patient was a 62-year-old woman that presented to clinic with a 9-month history of vertigo, progressive bilateral sensorineural hearing loss, diplopia, oscillopsia, ataxia and bilateral tremor. Her MRI brain obtained 8 months after symptom onset showed T2 hyperintense lesions in the inferior cerebellar hemispheres and right medial hippocampus with mild contrast enhancement in these areas. Cerebral spinal fluid analysis showed a lymphocytic pleocytosis, elevated protein, and negative infectious work-up. She completed 5 days of intravenous methylprednisolone and continued a steroid taper. She noted mild to moderate improvement in tremors, gait, and diplopia after steroids. Her symptoms, however worsened as she tapered her steroid dose. Serum KLHL11 antibody levels were positive at a titer of 1:7680. Computed tomography of the chest, abdomen and pelvis did not reveal any

evidence of malignancy. However, whole body proton emission tomography/computed tomography (PET CT) revealed a large hypermetabolic aortocaval mass soft tissue mass. A biopsy of the mass showed pathology consistent with a metastatic carcinoma of gynecologic origin for which the patient is undergoing chemotherapy with plans for possible tumor debulking.

Conclusions

This case highlights the importance of considering KLHL-11 encephalitis in female patients presenting with rhombencephalitis, and the need for adequate malignancy evaluation in this disorder.

Disclosure: Dr. Agyei has nothing to disclose. Dr. Gupta has nothing to disclose.

Immunotherapy With Subcutaneous Immunoglobulin or Plasmapheresis in Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Renee Nelson, Katrina Kesterson, Jill Schofield, Svetlana Blitshteyn

Objective

To assess improvement in autonomic symptoms and functional impairment following immunotherapy with subcutaneous immunoglobulin (SCIG) or plasmapheresis (PLEX) in patients with postural orthostatic tachycardia syndrome (POTS).

Background

POTS is a common autonomic disorder defined by an increased heart rate of at least 30 bpm within 10 minutes of standing or a tilt table test, accompanied by orthostatic intolerance, fatigue, dizziness, and headache. Despite pharmacologic and non-pharmacologic therapy, the marked functional impairment associated with POTS reflects great need for improved treatment. Autoimmunity has emerged as a leading etiology of POTS, with case series describing successful treatment with IVIG. To our knowledge, treatment with SCIG has not been described previously.

Design/Methods

Clinical history of seven patients with POTS treated with SCIG or PLEX was reviewed. Response to treatment was assessed using COMPASS-31 and functional ability scale (FAS) completed retrospectively pre- and 3-12 months post-treatment with SCIG or PLEX. Patients with comorbid defined autoimmune disorders or immune deficiency requiring treatment with immunotherapy were excluded from the study.

Results

Of seven patients, all female, ages 28-57, five received SCIG and two received PLEX. Four had comorbid small fiber neuropathy and five had various positive antibodies at low titers. Across all patients, COMPASS-31 and FAS scores improved an average of 50% and 21%, respectively. Six patients were able to discontinue or reduce oral medications and five reported being able to return to work or school. No serious adverse events were reported.

Conclusions

Patients with POTS experienced significant functional improvement with reduction in autonomic symptoms following immunotherapy with SCIG or PLEX. This case series suggests that SCIG and PLEX may be safe and effective treatments for patients with severe POTS refractory to standard therapies. Randomized controlled trials are needed to determine the efficacy and safety of these long-term therapies.

Disclosure: Miss Nelson has nothing to disclose. Dr. Kesterson has nothing to disclose. Prof. Schofield has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for IgNS. Dr. Blitshteyn has received personal compensation in the range of \$10,000-\$49,999 for serving as an Expert

Neurology®

CASPR-2 Antibody Associated Autoimmunity in the Setting of COVID-19 (Infection, Vaccination, or Both?) and Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

Neda Sattarnezhad, Jamie McDonald, Anna Tomczak, et al.

Neurology 2022;99;S67-S68

DOI 10.1212/01.wnl.0000903540.76175.dc

This information is current as of December 5, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/99/23_Supplement_2/S67.2.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Cerebrospinal Fluid http://n.neurology.org/cgi/collection/cerebrospinal_fluid CT http://n.neurology.org/cgi/collection/ct Low pressure syndrome http://n.neurology.org/cgi/collection/low_pressure_syndrome
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

